

Welcome

Tēnā koutou kātoa. I would like to extend a very warm welcome to the Otago Spotlight Series: Cardiovascular Disease Symposium. This is the second event in a series at which we are showcasing the research strengths in health sciences at the University of Otago. We are delighted to share our world-class research into cardiovascular disease (CVD) with you today.

The Division of Health Sciences at the University of Otago has an enviable reputation for research excellence and innovation. Our ground-breaking research underpins many advances in health policy and practice and the understanding of health and disease, both here in New Zealand, and globally.

Otago has significant depth and breadth in cardiovascular disease research. Our staff are leaders in the fields of CVD epidemiology, control and prevention, risk prediction, genetics, and the development of new diagnostics and treatments. We have expertise in health inequalities and in Māori and Pacific health, and are dedicated to undertaking research relevant to New Zealand's unique population groups.

Reducing the burden of CVD is a key priority for New Zealand. This can only be achieved by partnering with stakeholders and communities, and generating world-class research, and translating our research findings into innovative health policy, practice and technologies.

Today, stakeholders will have the chance to meet with researchers and to discuss the future of CVD research in New Zealand – its needs and its priorities. We would value your input on what you see as key priorities for the future of cardiovascular research in New Zealand.

I would like to thank today's speakers and attendees and I encourage you to keep in touch.



Professor Peter Crampton PRO-VICE-CHANCELLOR DIVISION OF HEALTH SCIENCES UNIVERSITY OF OTAGO

Cardiovascular Disease Research at Otago: Setting the Scene

Mortality from coronary heart disease and stroke has been declining over the past 40 years or so in New Zealand and many other relatively affluent westernised societies. It is difficult to disentangle the possible explanations, but improved treatment of those experiencing an acute event, early detection, better management of risk factors, and population measures which have helped to achieve a reduction in cigarette smoking and cholesterol levels, have undoubtedly all contributed.

While encouraging, these trends do not support complacency. CVD remains a leading cause of premature mortality and serious ill-health worldwide. This is true for many countries and population groups with previously low CVD rates, and in ageing populations – even in the presence of falling rates overall. Particularly worrying is the trend towards a changing pattern of risk factors for CVD. Obesity and diabetes have long been known to be associated with an increased risk of CVD. With these diseases having reached epidemic proportions in New Zealand and elsewhere, they are becoming increasingly important causes of CVD. Failure to reverse the epidemics of obesity and diabetes has the potential to undermine the health gains which have been achieved in terms of reducing the overall burden of CVD in recent times.

The University of Otago has a proud history of CVD research. Sir Horace Smirk was appointed to the Chair of Medicine at Otago in 1942. He was a pioneer in the treatment of hypertension with ganglion-blocking drugs such as hexamethonium and has received considerable credit for his contribution to establishing the benefits of treating raised blood pressure. Research in this field was continued by Professor Olaf Simpson who provided much of the crucial evidence underlying the current therapeutic treatments for hypertension. In the 1950s, Professor John Hunter was responsible for one of the early case control studies of myocardial infarction which demonstrated the importance of cholesterol as a risk factor. World leading lipid research continued when he was joined by Professor Ted Nye who was also a pioneer in the field of cardiac rehabilitation.

Today's talks will provide a snapshot of the CVD research being carried out by a new generation of researchers at Otago – both established scientists and emerging researchers. The talks will address questions from across the CVD continuum and provide examples of our progress in prevention, risk prediction, the development of new diagnostic tools and treatments, and the logistics of delivering affordable, equitable patient care in a tightly constrained healthcare system.

Thank you for attending today and we value any input you might wish to share with us.



Professor Jim Mann
DEPARTMENTS OF MEDICINE AND HUMAN NUTRITION
UNIVERSITY OF OTAGO

Programme

9.00-9.15am N	1it	ЛI
---------------	-----	----

Session One	
9.15-9.40	Professor Jim Mann (Medicine, Dunedin School of Medicine) Overview and nutrition research
9.40-10.00	Professor Nick Wilson (Public Health, University of Otago, Wellington) Modelling the impact of tobacco control interventions
10.00-10.20	Dr Rachael McLean (Preventive and Social Medicine, Dunedin School of Medicine) Dietary salt and cardiovascular disease: Evidence to policy
10.20-10.40	Professor Sally McCormick (Biochemistry, Otago School of Medical Sciences) Lipoproteins in heart disease
10.40-11.15	Morning Tea
Session Two	
11.15-11.35	Dr Pete Jones (Physiology, Otago School of Medical Sciences) Understanding arrhythmias
11.35-11.55	Dr Anna Pilbrow (Medicine, University of Otago, Christchurch) Discovering new risk markers for heart disease in 'junk DNA'
11.55-12.15	Professor Vicky Cameron and Dr Allamanda Faatoese (Medicine, University of Otago, Christchurch) Understanding cardiovascular risk in Māori and Pacific peoples
12.15-12.35	Professor Tony Blakely and Dr Nisha Nair (Public Health, University of Otago, Wellington) Sodium reduction and aortic aneurysm screening interventions – what might the health impact be?
12.35-1.40 1.00	Lunch Tour of the environmental chamber, Centre for Translational Physiology
Session Three	e
1.40-2.00	A/P Shieak Tzeng (Surgery, University of Otago, Wellington) Translating waveforms and protons into acute stroke management
2.00-2.20	Professor Andre van Rij (Surgical Sciences, Dunedin School of Medicine) Aortic aneurysm screening
2.20-2.40	Student presenters
2.40-3.00	Professor Mark Richards (Medicine, University of Otago, Christchurch) Improving diagnostic, prognostic and therapeutic biomarkers in heart disease
3.00-3.30	Discussion involving Dr Gerry Devlin from the National Heart Foundation and wrap up
3.30	Afternoon Tea
4.00	Taxis depart for flights to Dunedin and Christchurch

Contribute your views on Cardiovascular Disease Priorities

The Healthier Lives – *He Oranga Hauora* National Science Challenge is a national research collaboration dedicated to achieving healthier lives for all New Zealanders. The key to this is delivering the right prevention to the right population and the right treatment to the right patient.

Healthier Lives is working on the prevention and treatment of four of New Zealand's main non-communicable diseases:

- Cancer
- Cardiovascular disease
- Diabetes
- Obesity

Together, with others working in these fields, we will contribute to New Zealand's commitment to achieving the World Health Organisation goals of:

- Reducing the health burden of non-communicable diseases by 25% by 2025
- Reducing health inequalities between populations by 25% by 2025

We plan to do this in partnership with stakeholders and communities by generating world-class research, and translating our research findings into innovative health policy, practice and technology, designed for New Zealand's unique communities.

Healthier Lives has a major CVD research project underway and, in partnership with the Ministry of Health and the Health Research Council of New Zealand, is currently seeking proposals for further research into long term conditions. We are also looking ahead to identify gaps in the landscape where more research is needed. We would love to hear your views about the most important priorities for CVD research in New Zealand over the next 5 years.

Contribute your views at: healthier.lives@otago.ac.nz

Further information: healthierlives.co.nz/



He Oranga Hauora

Human Environmental Chamber

The Global Energetics and Environmental Simulation Suite (GENESIS) is a new research facility developed to support research into environmental disease interactions at the Centre for Translational Physiology, University of Otago, Wellington. GENESIS is capable of simulating temperatures from -10 to +50 degrees Celsius, 10-95% relative humidity and simulated altitude of up to 5400 metres. Additionally, GENESIS is equipped with precision gas sensors for monitoring human energy expenditure and whole body metabolism.

For information on how to access the facility for research, athletic training or commercial applications please contact the Facility Manager at: ctp.wellington@otago.ac.nz.

A guided tour of the facility will take place at 1pm.



Entries for the Student Poster Competition

POSTER NUMBER	TITLE, AUTHOR, DEPARTMENT
1	RECYCLING OF APOLIPOPROTEIN(a) AFTER PIgRKT-MEDIATED ENDOCYTOSIS OF LIPOPROTEIN(a) Monika Sharma ¹ , Greg Redpath ¹ , Michael Williams ² , Sally McCormick ¹ ¹Department of Biochemistry, Otago School of Medical Sciences. ²Department of Medicine, Dunedin School of Medicine
2	DOES AUTONOMIC DYSREGULATION REDUCE CARDIAC RESERVE IN TYPE 2 DIABETES? Genevieve Wilson¹, Luke Wilson¹, Regis Lamberts², Kamran Majeed³, Sudish Lal¹, Gerard Wilkins¹, James Baldi¹ ¹Department of Medicine, Dunedin School of Medicine; ²Department of Physiology, Otago School of Medical Sciences; ³Royal Adelaide Hospital, Adelaide, Australia
3	CaMKII MEDIATES VASCULAR SMOOTH MUSCLE CELL ACTIVATION CENTRAL TO THE DEVELOPMENT OF ATHEROSCLEROSIS Luke Worthington, Jeff Erickson, Alison Heather Department of Physiology, Otago School of Medical Sciences
4	CaMKII INHIBITION RESTORES CONTRACTILE PERFORMANCE IN CARDIAC MUSCLE FROM A RAT MODEL OF TYPE 2 DIABETES Lorna Daniels, Regis Lamberts, Fiona McDonald, Jeff Erickson Department of Physiology, Otago School of Medical Sciences and Heart Otago, University of Otago
5	RARE GENETIC VARIANTS IN THE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 2 (LRP2) GENE CONFER RISK FOR HYPERURICAEMIA IN NEW ZEALAND POLYNESIANS Tahzeeb Fatima¹, James Boocock¹, Tanya J Flynn¹, Lisa K Stamp², Nicola Dalbeth³, Hyon K Choi⁴, David B Mount⁵, Eli A Stahl⁶, Tony R Merriman¹ ¹Department of Biochemistry, Otago School of Medical Sciences; ²Department of Medicine, University of Otago, Christchurch; ³Department of Medicine, University of Auckland; ⁴Institute for Genomics and Multiscale Biology, Icahn School of Medicine, New York; ⁵Renal Divisions, Brigham and Women's Hospital and VA Boston Healthcare System, Harvard Medical School, Boston; ⁶Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston
6	QUALITATIVE EVALUATION OF PRIOR CARDIOVASCULAR RISK ASSESSMENT AND ITS EFFECTIVENESS IN PATIENTS PRESENTING WITH THEIR FIRST DIAGNOSIS OF ACUTE CORONARY SYNDROME Rosalind Poulgrain, Merrin Rutherford, Stewart Mann Department of Medicine, University of Otago, Wellington
7	HOT-WATER IMMERSION INCREASES LEG PERFUSION IN PERIPHERAL ARTERIAL DISEASE Kate Thomas ^{1,2} Andre Van Rij ¹ , James Cotter ² ¹ Department of Surgical Sciences, Dunedin School of Medicine. ² School of Physical Education, Sport and Exercise Sciences, University of Otago
8	PHYSICAL INACTIVITY CONTRIBUTES TO CARDIOVASCULAR RISK IN ADULTS WITH SYMPTOMS OF OBSTRUCTIVE SLEEP APNOEA HYPOPNOEA SYNDROME Sarah Rhodes¹, Ben Brockway², Margot Skinner¹ ¹Centre for Health Activity and Rehabilitation Research, School of Physiotherapy, University of Otago, ²Department of Medicine, Dunedin School of Medicine

9	ARE HIGH ALTITUDE POPULATIONS AT HIGH RISK OF HEART DISEASE?	
,	All and County Many Mad Washerd I Vance Des Destite	

- 9 ARE HIGH ALTITUDE POPULATIONS AT HIGH RISK OF HEART DISEASE?

 Nirmal Aryal, Stewart Mann, Mark Weatherall, Yadav Kumar, Deo Bhatta
 Department of Medicine, University of Otago, Wellington
- 10 INFLUENZA THE HIDDEN TRIGGER FOR CARDIOVASCULAR DISEASES
 Trang QT Khieu, Michael Baker, Nevil Pierse, Lucy Telfar-Barnard
 Department of Public Health, University of Otago, Wellington
- 11 ANTIHYPERTENSIVE MEDICINES UTILISATION: A DECADE-LONG NATIONWIDE STUDY OF OCTOGENARIANS, NONAGENARIANS AND CENTENARIANS

 Sujita Narayan, Prasad Nishtala

 Research in Pharmacoepidemiology (RiPE) Group, School of Pharmacy, University of Otago

Attendees

Surname First Name Organisation Heart Foundation Arcus Kim Nirmal Medicine UOW Arval Public Health UOW Atkinson lune Awmee Devindra Ministry of Health Bailey lennifer Ministry of Health Baldi Chris Medicine DSM Christine Medicine UOW Barthow Public Health UOW Blakely Tony Ministry of Health Boyd Matt Vicky Medicine UOC Cameron Ministry of Health Chester Sara Cleghorn Christina Public Health UOW Coleman Karen Radiation Therapy UOW Coleman Michele Health Sciences Administration Coleman Lin Capital Coast DHB Conner James Research & Enterprise Otago Crampton Peter Health Sciences Administration Cresswell Pip Capital Coast DHB Cunningham Ruth Public Health UOW Physiology OSMS **Daniels** Lorna Bronwyn Capital Coast DHB Davies Dension Haley Victoria University Heart Foundation Devlin Gerry Doolan-Noble General Practice & Rural Health DSM Fiona Dunbar lanet Capital Coast DHB Amanda Massey University Eng Ministry of Health **Ewers** Gillian Allamanda Medicine UOC Faatoese Tahzeeb **Biochemistry OSMS** Fatima Sophia Ministry of Health Faure Fleming Kirsty Roche Products Ltd Galvin Kerry Health Sciences Administration Gray **Emily** School of Physiotherapy James Ministry of Health Greenwell Research & Enterprise Otago Groves Christine Joanne Pharmacology & Toxicology OSMS Harrison Victoria Research & Enterprise Otago lameson Pete Physiology OSMS Jones Katare Rajesh Physiology OSMS Bronwyn Tertiary Education Commission Kelly Khashram Manar Surgery UOC Khieu Trang Public Health UOW Lane Jonathan **MBIE** Lewis Lynley Medicine UOC Ministry of Health Lyon Jane

Majumder

McCormick

McNicholas

Mann

Marra

McLean

Gitta

Carlo

Sally

Anne

Rachael

Jim

Email

KimA@heartfoundation.org.nz

nirmal.arval@otago.ac.nz june.atkinson@otago.ac.nz devindra awmee@moh.govt.nz Jennifer_Bailey@moh.govt.nz chris.baldi@otago.ac.nz christine.barthow@otago.ac.nz tony.blakely@otago.ac.nz Matt_Boyd@moh.govt.nz vicky.cameron@otago.ac.nz c/o Sophia Faure@moh.govt.nz cristina.cleghorn@otago.ac.nz karen.coleman@otago.ac.nz michele.coleman@otago.ac.nz Lin.coleman@ccdhb.org.nz james.conner@otago.ac.nz peter.crampton@otago.ac.nz pip.cresswell@ccdhb.org.nz ruth.cunningham@otago.ac.nz danlo676@student.otago.ac.nz Bronwyn.davies@ccdhb.org.nz Hayley.Denison@vuw.ac.nz GerryD@heartfoundation.org.nz fiona.doolan-noble@otago.ac.nz Janet.dunbar@ccdhb.org.nz A.J.Eng@massesy.ac.nz c/o devindra awmee@moh.govt.nz allamanda.faatoese@otago.ac.nz tahzeeb.fatima@otago.ac.nz Sophia_Faure@moh.govt.nz kirsty.fleming@roche.com kerry.galvin@otago.ac.nz emily.gray@otago.ac.nz c/o Sophia_Faure@moh.govt.nz christine.groves@otago.ac.nz joanne.harrison@otago.ac.nz victoria.jameson@otago.ac.nz pete.jones@otago.ac.nz rajesh.katare@otago.ac.nz Bronwen.Kelly@tec.govt.nz manar.khashram@gmail.com khitr138@student.otago.ac.nz Jonathan.Lane@mbie.govt.nz lynley.lewis@otago.ac.nz Jane_Lyon@moh.govt.nz gitta.majumder@ccdhb.org.nz jim.mann@otago.ac.nz pharmacy.dean@otago.ac.nz sally.mccormick@otago.ac.nz rachael.mclean@otago.ac.nz Anne_McNicholas@moh.govt.nz

Capital Coast DHB

School of Pharmacy

Biochemistry OSMS

Ministry of Health

Preventive & Social Medicine DSM

Medicine DSM

Surname	First Name	Organisation	Email
Middleditch	Diane	Capital Coast DHB	Diane.middleditch@ccdhb.org.nz
Miharsa	Lea	Ministry of Health	c/o devindra_awmee@moh.govt.nz
Millar	Elinor	Hutt Valley DHB	Elinor.millar@huttvalleydhb.org.nz
Murphy	Chris	Capital Coast DHB	Chris.murphy@ccdhb.org.nz
Nair	Nisha	Public Health UOW	nisha.nair@otago.ac.nz
Narayan	Sujita	School of Pharmacy	sujita.narayan@otago.ac.nz
O'Hallahan	Jane	Ministry of Health	c/o Anne_McNicholas@moh.govt.nz
O'Reilly	Kate	Capital Coast DHB	Kate.o'reilly@ccdhb.org.nz
Peacock	Leigh	Well Heart	wellheart1@gmail.com
Pickthorne	Judy	Hutt Valley DHB	jude.pickthorne@huttvalleydhb.org.nz
Pilbrow	Anna	Medicine UOC	anna.pilbrow@otago.ac.nz
Poulgrain	Rosalind	Medicine UOW	pouro271@student.otago.ac.nz
Prickett	Tim	Medicine UOC	tim.prickett@otago.ac.nz
Read	Morgayn	Biochemistry OSMS	morgayn.read@otago.ac.nz
Rendle	Bronwyn	Ministry of Health	c/o Anne_McNicholas@moh.govt.nz
Rhodes	Sarah	School of Physiotherapy	rhosa130@student.otago.ac.nz
Richards	Mark	Medicine UOC	mark.richards@cdhb.health.nz
Rose	Deanna	Ministry of Health	c/o devindra_awmee@moh.govt.nz
Roseingrave	June	Wairarapa DHB	June.Roseingrave@wairarapa.dhb.org.nz
Ross	Cecilia	Capital Coast DHB	Cecilia.ross@ccdhb.org.nz
Safarti	John		jlsarfati@icloud.com
Sammut	Ivan	Pharmacology & Toxicology OSMS	ivan.sammut@otago.ac.nz
Schaaf	David	Ministry of Health	David_Schaaf@moh.govt.nz
Schwenke	Daryl	Physiology OSMS	daryl.schwenke@otago.ac.nz
Scott	Nicola	Medicine UOC	nicola.scott@otago.ac.nz
Scott	Beverley	Capital Coast DHB	beverley.scott@ccdhb.org.nz
Sharma	Monika	Biochemistry OSMS	shamo689@student.otago.ac.nz
Stanley	James	Public Health UOW	james.stanley@otago.ac.nz
Sutherland	Biddy	Hutt Valley DHB	gbrjs@globe.net.nz
Thomas	Kate	Surgical Sciences DSM	kate.thomas@otago.ac.nz
Trower	Jill Claire a le	Wairarapa DHB	cardiac.outreach@wairarapa.dhb.org.nz
Tzeng	Shieak	Surgery UOW	shieak.tzeng@otago.ac.nz
Van Rij	Andre	Surgical Sciences DSM	andre.vanrij@otago.ac.nz
Walsh	Emily	Capital Coast DHB	Emily.walsh@ccdhb.org.nz
Ward Weerasekera	Margaret	Capital Coast DHB	Margaret.ward@ccdhb.org.nz
	Renuka	Ministry of Health	c/o devindra_awmee@moh.govt.nz
Wilson Wilson	Genevieve Luke	Medicine DSM	genevieve527@gmail.com
Wilson	Luke Nick	Medicine DSM Public Health UOW	luke.wilson@otago.ac.nz nick.wilson@otago.ac.nz
Worthington	Luke	Physiology OSMS	worlu489@student.otago.ac.nz
Wylie	Donna	Capital Coast DHB	Donna.wylie@ccdhb.org.nz
Zhang	Wei	Public Health UOW	wei.zhang@otago.ac.nz
21 Iai ig	V V □ I	i ablic i lealth oow	wei.znangwotago.ac.nz





Otago Spotlight Series
Cardiovascular Disease
otago.ac.nz/healthsciences